litlas
Log inCreate account

Douglas Yee

Active 1988–2025

128
Papers
22,037
Citations
84
h-index
120
i10-index

Citations

Citations per year for Douglas Yee1982: 1 citations1989: 4 citations1990: 18 citations1991: 22 citations1992: 35 citations1993: 34 citations1994: 25 citations1995: 34 citations1996: 28 citations1997: 30 citations1998: 44 citations1999: 54 citations2000: 84 citations2001: 88 citations2002: 103 citations2003: 128 citations2004: 123 citations2005: 132 citations2006: 158 citations2007: 165 citations2008: 199 citations2009: 168 citations2010: 176 citations2011: 234 citations2012: 239 citations2013: 204 citations2014: 196 citations2015: 203 citations2016: 162 citations2017: 223 citations2018: 178 citations2019: 540 citations2020: 638 citations2021: 652 citations2022: 474 citations2023: 427 citations2024: 631 citations2025: 346 citations2026: 6 citations1983–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,773 citing papers, 30.6% of this breakdownChina: 860 citing papers, 9.5% of this breakdownUnited Kingdom: 579 citing papers, 6.4% of this breakdownItaly: 438 citing papers, 4.8% of this breakdownCanada: 373 citing papers, 4.1% of this breakdownGermany: 328 citing papers, 3.6% of this breakdownAustralia: 287 citing papers, 3.2% of this breakdownFrance: 252 citing papers, 2.8% of this breakdownJapan: 250 citing papers, 2.8% of this breakdownSpain: 245 citing papers, 2.7% of this breakdownNetherlands: 203 citing papers, 2.2% of this breakdownIndia: 185 citing papers, 2.1% of this breakdown
0%30.6%Other 25.2%

Institutions

Fields

  • Medicine51.4%
  • Biochemistry, Genetics and Molecular Biology39.1%
  • Immunology and Microbiology2.6%
  • Environmental Science1.2%
  • Neuroscience1.1%
  • Materials Science0.8%
  • Other3.8%

Topics

  • Metabolism, Diabetes, and Cancer5.9%
  • Growth Hormone and Insulin-like Growth Factors3.9%
  • Breast Cancer Treatment Studies2.8%
  • Cancer Immunotherapy and Biomarkers2.8%
  • Cancer Risks and Factors2.6%
  • Cancer, Hypoxia, and Metabolism2.5%
  • Other79.5%

Coauthors

All papers

Open in search
  1. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

    Authors: Rita Nanda, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne M. Wallace, A. Jo Chien, Andres Forero‐Torres, Erin D. Ellis, Heather Han, Amy S. Clark, Kathy S. Albain, Judy C. Boughey, Nora Jaskowiak, Anthony Elias, Claudine Isaacs, Kathleen Kemmer, Teresa Helsten, Melanie Majure, Erica Stringer-Reasor, Catherine Parker, Marie Catherine Lee, Tufia C. Haddad, Ronald Cohen, Smita Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam L. Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Richard B. Schwab, W. Fraser Symmans, Laura van ‘t Veer, Douglas Yee, Angela DeMichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Donald A. Berry, Laura J. Esserman - JAMA Oncology 2020 cited by 706

  2. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

    Authors: Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee, Zelos Zhu, Mark Jesus M. Magbanua, Rosalyn W. Sayaman, Nicholas O’Grady, Amrita Basu, Amy L. Delson, Jean Philippe Coppé, Ruixiao Lu, Jerome J. Braun, Smita Asare, Laura Sit, Jeffrey B. Matthews, Jane Perlmutter, Nola M. Hylton, Minetta C. Liu, Paula R. Pohlmann, W. Fraser Symmans, Hope S. Rugo, Claudine Isaacs, Angela DeMichele, Douglas Yee, Donald A. Berry, Lajos Pusztai, Emanuel F. Petricoin, Gillian L. Hirst, Laura J. Esserman, Laura van ‘t Veer - Cancer Cell 2022 cited by 326

  3. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

    Authors: Lajos Pusztai, Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace, Erica String-Reasor, Judy C. Boughey, A. Jo Chien, Anthony Elias, Heather Beckwith, Rita Nanda, Kathy S. Albain, Amy S. Clark, Kathleen Kemmer, Kevin Kalinsky, Claudine Isaacs, Alexandra Thomas, Rebecca Shatsky, Theresa L. Helsten, Andres Forero‐Torres, Minetta C. Liu, Lamorna Brown Swigart, Emmanuel Petricoin, Julia Wulfkuhle, Smita Asare, Amy Wilson, Ruby Singhrao, Laura Sit, Gillian L. Hirst, Scott Berry, Ashish Sanil, Adam L. Asare, Jeffrey B. Matthews, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Douglas Yee, Laura J. van’t Veer, Nola M. Hylton, Angela DeMichele, Donald A. Berry, Laura J. Esserman - Cancer Cell 2021 cited by 330

  4. Diabetes and Cancer

    Authors: Edward L. Giovannucci, David M. Harlan, Michael C. Archer, Richard M. Bergenstal, Susan M. Gapstur, Laurel A. Habel, Michaël Pollak, Judith G. Regensteiner, Douglas Yee - Diabetes Care 2010 cited by 2,244

  5. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

    Authors: Mark Jesus M. Magbanua, Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova, Gillian L. Hirst, Christina Yau, Denise M. Wolf, Wen Li, Amy L. Delson, Smita Asare, Minetta C. Liu, Kathy S. Albain, A. Jo Chien, Andres Forero‐Torres, Claudine Isaacs, Rita Nanda, Debu Tripathy, Angel Rodriguez, Himanshu Sethi, Alexey Aleshin, Matthew Rabinowitz, Jane Perlmutter, W. Fraser Symmans, Douglas Yee, Nola M. Hylton, Laura J. Esserman, Angela DeMichele, Hope S. Rugo, Laura van ‘t Veer - Cancer Cell 2023 cited by 171

  6. Diabetes and Cancer: A Consensus Report

    Authors: Edward L. Giovannucci, David M. Harlan, Michael C. Archer, Richard M. Bergenstal, Susan M. Gapstur, Laurel A. Habel, Michaël Pollak, Judith G. Regensteiner, Douglas Yee - CA A Cancer Journal for Clinicians 2010 cited by 1,062

  7. Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

    Authors: Douglas Yee, Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain, Yunn-Yi Chen, Gregor Krings, Shi Wei, Shuko Harada, Brian Datnow, Oluwole Fadare, Molly Klein, Stefan E. Pambuccian, Beiyun Chen, Kathi Adamson, Sharon B. Sams, Paulette Mhawech‐Fauceglia, Anthony M. Magliocco, Mike Feldman, Mara H. Rendi, Husain Sattar, Jay Zeck, Idris Tolgay Ocal, Ossama Tawfik, Lauren LeBeau, Sunati Sahoo, Tuyethoa N. Vinh, A. Jo Chien, Andres Forero‐Torres, Erica Stringer-Reasor, Anne M. Wallace, Lajos Pusztai, Judy C. Boughey, Erin D. Ellis, Anthony Elias, Janice Lu, Julie E. Lang, Hyo S. Han, Amy S. Clark, Rita Nanda, Donald W. Northfelt, Qamar J. Khan, Rebecca K. Viscusi, David Euhus, Kirsten K. Edmiston, Jane Yuet Ching Hui, Kathleen Kemmer, John W. Park, Minetta C. Liu, Olufunmilayo I. Olopade, Brian Leyland‐Jones, Debasish Tripathy, Stacy L. Moulder, Hope S. Rugo, Richard B. Schwab, Shelly S. Lo, Teresa Helsten, Heather Beckwith, Patricia Haugen, Nola M. Hylton, Laura J. van’t Veer, Jane Perlmutter, Michelle Melisko, Amy Wilson, Garry Peterson, Adam L. Asare, Meredith Buxton, Melissa Paoloni, Julia L. Clennell, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Jeffrey B. Matthews, Smita Asare, Ashish Sanil, Scott Berry, Laura J. Esserman, Donald A. Berry - JAMA Oncology 2020 cited by 225

  8. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer

    Authors: Haiyun Wang, Douglas Yee - Current Breast Cancer Reports 2019 cited by 167

  9. Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

    Authors: Hope S. Rugo, Olufunmilayo I. Olopade, Angela DeMichele, Christina Yau, Laura van ‘t Veer, Meredith Buxton, Michael Hogarth, Nola M. Hylton, Melissa Paoloni, Jane Perlmutter, W. Fraser Symmans, Douglas Yee, A. Jo Chien, Anne M. Wallace, Henry G. Kaplan, Judy C. Boughey, Tufia C. Haddad, Kathy S. Albain, Minetta C. Liu, Claudine Isaacs, Qamar J. Khan, Julie E. Lang, Rebecca K. Viscusi, Lajos Pusztai, Stacy L. Moulder, Jane Yuet Ching Hui, Kathleen Kemmer, Anthony Elias, Kirsten K. Edmiston, David Euhus, Barbara Haley, Rita Nanda, Donald W. Northfelt, Debasish Tripathy, William C. Wood, Cheryl A. Ewing, Richard B. Schwab, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Donald A. Berry, Laura J. Esserman - New England Journal of Medicine 2016 cited by 555

  10. APOBEC3B is an enzymatic source of mutation in breast cancer

    Authors: Michael B. Burns, Lela Lackey, Michael A. Carpenter, Anurag S. Rathore, Allison M. Land, Brandon Leonard, Eric W. Refsland, Delshanee Kotandeniya, Natalia Tretyakova, Jason B. Nikas, Douglas Yee, Nuri A. Temiz, Duncan Donohue, Rebecca M. McDougle, William L. Brown, Emily K. Law, Reuben S. Harris - Nature 2013 cited by 888

  11. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer

    Authors: W. Fraser Symmans, Christina Yau, Yunn-Yi Chen, Ronald Balassanian, Molly Klein, Lajos Pusztai, Rita Nanda, Barbara A. Parker, Brian Datnow, Gregor Krings, Shi Wei, Michael D. Feldman, Xiuzhen Duan, Beiyun Chen, Husain Sattar, Laila Khazai, Jay Zeck, Sharon B. Sams, Paulette Mhawech‐Fauceglia, Mara H. Rendi, Sunati Sahoo, Idris Tolgay Ocal, Fang Fan, Lauren LeBeau, Tuyethoa N. Vinh, Megan L. Troxell, A. Jo Chien, Anne M. Wallace, Andres Forero‐Torres, Erin D. Ellis, Kathy S. Albain, Rashmi K. Murthy, Judy C. Boughey, Minetta C. Liu, Barbara Haley, Anthony Elias, Amy S. Clark, Kathleen Kemmer, Claudine Isaacs, Julie E. Lang, Hyo S. Han, Kirsten K. Edmiston, Rebecca K. Viscusi, Donald W. Northfelt, Qamar J. Khan, Brian Leyland‐Jones, Sara J. Venters, Sonal Shad, Jeffrey B. Matthews, Smita Asare, Meredith Buxton, Adam L. Asare, Hope S. Rugo, Richard B. Schwab, Teresa Helsten, Nola M. Hylton, Laura van ‘t Veer, Jane Perlmutter, Angela DeMichele, Douglas Yee, Donald A. Berry, Laura J. Esserman - JAMA Oncology 2021 cited by 106

  12. Adaptive Randomization of Neratinib in Early Breast Cancer

    Authors: John W. Park, Minetta C. Liu, Douglas Yee, Christina Yau, Laura van ‘t Veer, W. Fraser Symmans, Melissa Paoloni, Jane Perlmutter, Nola M. Hylton, Michael Hogarth, Angela DeMichele, Meredith Buxton, A. Jo Chien, Anne M. Wallace, Judy C. Boughey, Tufia C. Haddad, Jane Yuet Ching Hui, Kathleen Kemmer, Henry G. Kaplan, Claudine Isaacs, Rita Nanda, Debasish Tripathy, Kathy S. Albain, Kirsten K. Edmiston, Anthony Elias, Donald W. Northfelt, Lajos Pusztai, Stacy L. Moulder, Julie E. Lang, Rebecca K. Viscusi, David Euhus, Barbara Haley, Qamar J. Khan, William C. Wood, Michelle Melisko, Richard B. Schwab, Teresa Helsten, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Laura J. Esserman, Donald A. Berry - New England Journal of Medicine 2016 cited by 460

  13. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial

    Authors: A. Jo Chien, Debasish Tripathy, Kathy S. Albain, W. Fraser Symmans, Hope S. Rugo, Michelle Melisko, Anne M. Wallace, Richard B. Schwab, Teresa Helsten, Andres Forero‐Torres, Erica Stringer-Reasor, Erin D. Ellis, Henry G. Kaplan, Rita Nanda, Nora Jaskowiak, Rashmi K. Murthy, Constantine Godellas, Judy C. Boughey, Anthony Elias, Barbara Haley, Kathleen Kemmer, Claudine Isaacs, Amy S. Clark, Julie E. Lang, Janice Lu, Larissa A. Korde, Kirsten K. Edmiston, Donald W. Northfelt, Rebecca K. Viscusi, Douglas Yee, Jane Perlmutter, Nola M. Hylton, Laura J. van’t Veer, Angela DeMichele, Amy Wilson, Garry Peterson, Meredith Buxton, Melissa Paoloni, Julia L. Clennell, Scott Berry, Jeffrey B. Matthews, Katherine Steeg, Ruby Singhrao, Gillian L. Hirst, Ashish Sanil, Christina Yau, Smita Asare, Donald A. Berry, Laura J. Esserman - Journal of Clinical Oncology 2020 cited by 112

  14. Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

    Authors: Rebecca Shatsky, Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian, Butch Tsiatis, Anne M. Wallace, A. Jo Chien, Erica Stringer-Reasor, Judy C. Boughey, Coral Omene, Mariya Rozenblit, Kevin Kalinsky, Anthony Elias, Christos Vaklavas, Heather Beckwith, Nicole Williams, Mili Arora, Chaitali Nangia, Evanthia T. Roussos Torres, Brittani Thomas, Kathy S. Albain, Amy S. Clark, Carla I. Falkson, Dawn L. Hershman, Claudine Isaacs, Alexandra Thomas, Jennifer F. Tseng, Amy Sanford, Kay T. Yeung, Sarah G Boles, Yunni Yi Chen, Laura A. Huppert, Nusrat Jahan, Catherine Parker, Karthik V. Giridhar, Frederick M. Howard, Mallory Blackwood, Tara Sanft, Wen Li, Natsuko Onishi, Adam L. Asare, Philip Beineke, Peter Norwood, Lamorna Brown Swigart, Gillian L. Hirst, Jeffrey B. Matthews, Brian A. Moore, W. Fraser Symmans, Elissa R. Price, Diane Heditsian, Barbara LeStage, Jane Perlmutter, Paula R. Pohlmann, Angela DeMichele, Douglas Yee, Laura van ‘t Veer, Nola M. Hylton, Laura J. Esserman - Nature Medicine 2024 cited by 40

  15. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer

    Authors: Emily K. Law, Anieta M. Sieuwerts, Kelly LaPara, Brandon Leonard, Gabriel J. Starrett, Amy M. Molan, Nuri A. Temiz, Rachel I. Vogel, Marion E. Meijer‐van Gelder, Fred C.G.J. Sweep, Paul N. Span, John A. Foekens, John W.M. Martens, Douglas Yee, Reuben S. Harris - Science Advances 2016 cited by 240

  16. Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer

    Authors: Michael A. Carpenter, Nuri A. Temiz, Mahmoud A. Ibrahim, Matthew C. Jarvis, Margaret R. Brown, Prokopios P. Argyris, William L. Brown, Gabriel J. Starrett, Douglas Yee, Reuben S. Harris - PLoS Genetics 2023 cited by 50

  17. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

    Authors: Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara Haley, Hyo S. Han, Andres Forero‐Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel L. Yung, Debu Tripathy, Rita Nanda, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam L. Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela DeMichele - Nature Communications 2021 cited by 73

  18. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update

    Authors: Beverly Moy, R. Bryan Rumble, Steven E. Come, Nancy E. Davidson, Angelo Di Leo, Julie R. Gralow, Gabriel N. Hortobagyi, Douglas Yee, Ian E. Smith, Mariana Chavez-MacGregor, Rita Nanda, Heather L. McArthur, Laura Spring, Katherine E. Reeder-Hayes, Kathryn J. Ruddy, Paul S. Unger, Shaveta Vinayak, William J. Irvin, Avan Armaghani, Michael A. Danso, Natalie Dickson, Sophie S. Turner, Cheryl L. Perkins, Lisa A. Carey - Journal of Clinical Oncology 2021 cited by 67

  19. Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment

    Authors: Nathan Ungerleider, Sonia G. Rao, Ashkan Shahbandi, Douglas Yee, Tianhua Niu, Wesley D. Frey, James G. Jackson - Breast Cancer Research 2018 cited by 105

  20. Quantum Dots for Cancer Diagnosis and Therapy: Biological and Clinical Perspectives

    Authors: Hua Zhang, Douglas Yee, Chun Wang - Nanomedicine 2008 cited by 255

  21. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth.

    Authors: Kalpna Gupta, Smita Kshirsagar, Liming Chang, Robert A. Schwartz, Ping‐Yee Law, Douglas Yee, Robert P. Hebbel - 2002 cited by 532

  22. Revisiting the IGF-1R as a breast cancer target

    Authors: Roudy Chiminch Ekyalongo, Douglas Yee - npj Precision Oncology 2017 cited by 115

  23. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

    Authors: Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero‐Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara Haley, Anthony Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia Wulfkuhle, Lamorna Brown Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van’t Veer, Donald A. Berry, Laura J. Esserman - npj Breast Cancer 2021 cited by 29

  24. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas

    Authors: Xin Huang, Haein Park, J.T. Greene, James Pao, Erin Mulvey, Sophia X. Zhou, Catherine M. Albert, Fred Moy, Deepali Sachdev, Douglas Yee, Christoph Rader, Carl V. Hamby, David M. Loeb, Mitchell S. Cairo, Xianzheng Zhou - PLoS ONE 2015 cited by 108